Clinical Trials
58 trialsNCT06567782 2026-05-22
AZUR-4
GlaxoSmithKline
Phase 2 Recruiting
NCT05513742 2026-05-06
COMPANION-003
Compass Therapeutics
Phase 2 Completed
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT05983367 2026-02-20
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Inspirna, Inc.
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT04291105 2025-03-26
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
Phase 2 Recruiting
NCT05456165 2024-12-31
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
Phase 2 Withdrawn
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT03883802 2022-12-09
NeoFox
WntResearch AB
Phase 2 Unknown
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT00089635 2022-11-07
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Amgen
Phase 2 Completed
NCT01464593 2022-10-13
ABLATE
Imunon
Phase 2 Terminated
NCT01505166 2021-11-01
FANG-CLM
Gradalis, Inc.
Phase 2 Terminated
NCT00361842 2021-07-02
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT04145193 2020-09-21
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
Phase 2 Withdrawn
NCT00192114 2020-08-06
Enzastaurin for Patients With Metastatic Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02425683 2020-02-10
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
Phase 2 Terminated
NCT01111604 2019-08-06
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01925274 2019-01-08
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT02305758 2018-11-20
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
AbbVie
Phase 2 Completed
NCT00094809 2018-10-17
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Amgen
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00896454 2018-10-17
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Phase 2 Completed
NCT00845039 2018-07-02
FC-4
Eli Lilly and Company
Phase 2 Terminated
NCT00398879 2018-03-14
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
AEterna Zentaris
Phase 2 Completed
NCT00388700 2018-02-14
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT02119676 2018-02-13
Study of Ruxolitinib in Colorectal Cancer Patients
Incyte Corporation
Phase 2 Terminated
NCT01832857 2016-12-29
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Cornerstone Pharmaceuticals
Phase 2 Terminated
NCT01549535 2016-11-25
Polyp Detection With The Peerscope Systemâ„¢
PeerMedical Ltd.
Phase 2 Completed
NCT00813605 2016-10-27
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
NantCell, Inc.
Phase 2 Completed
NCT00454116 2016-10-07
A Phase II, Double Blind Study of 2 Doses of ZACTIMAâ„¢(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Sanofi
Phase 2 Completed
NCT00851084 2016-06-07
AFFIRM
Sanofi
Phase 2 Completed
NCT02002689 2016-05-02
SIGNATURE
Novartis
Phase 2 Terminated
NCT00022698 2016-04-15
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00332163 2016-02-23
STEPP
Amgen
Phase 2 Completed
NCT00411450 2016-02-15
PRECEPT
Amgen
Phase 2 Completed
NCT00752570 2015-09-02
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Amgen
Phase 2 Completed
NCT01714466 2014-11-20
Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy
Norgine
Phase 2 Completed
NCT00862784 2014-06-17
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00675012 2014-05-30
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
AGC Biologics S.p.A.
Phase 2 Completed
NCT00035087 2013-12-04
EPO906 Therapy in Patients With Advanced Colorectal Cancer
Novartis
Phase 2 Completed
NCT00096083 2013-10-23
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Phase 2 Completed
NCT00707889 2013-05-15
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
AbbVie
Phase 2 Completed
NCT00111774 2013-05-14
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Amgen
Phase 2 Completed
NCT01329809 2013-04-10
Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors
Jennerex Biotherapeutics
Phase 2 Terminated
NCT00569335 2012-11-02
Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00988936 2012-08-22
K5-101
Siemens Molecular Imaging
Phase 2 Completed
NCT00080834 2012-05-16
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
Daiichi Sankyo
Phase 2 Completed